# OnCo record lilrb2 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/lilrb2/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "lilrb2" ;
  schema:name "LILRB2 (ILT4)"@en ;
  schema:alternateName "ILT4"@en, "LIR-2"@en, "CD85d"@en, "leukocyte immunoglobulin like receptor B2"@en, "LILRB2" ;
  schema:description "LILRB2 is a brake on monocytes and dendritic cells that reads HLA-G and other HLA class I molecules and keeps them in a tolerant, tumour-friendly state. The antibody MK-4830 blocks it and is in phase 2 with pembrolizumab."@en ;
  schema:url <https://onco.cc/targets/lilrb2/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606>, <https://www.uniprot.org/uniprotkb/Q8N423/entry>, <https://www.ncbi.nlm.nih.gov/gene/10288>, <https://clinicaltrials.gov/study/NCT05446870>, <https://europepmc.org/article/MED/28638976> ;
  onco:tag "checkpoint-map" ;
  onco:targetClass "checkpoint" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6606>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131042>, <https://www.uniprot.org/uniprotkb/Q8N423/entry>, <https://www.ncbi.nlm.nih.gov/gene/10288> ;
  onco:related <https://onco.cc/targets/lilrb1/>, <https://onco.cc/targets/hla-a/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:pathways <https://onco.cc/pathways/cancer-immunity-cycle/> .